The Fat Side of the Endocannabinoid System: Role of Endocannabinoids in the Adipocyte

MatiasIsabelle,; BelluomoIlaria,; CotaDaniela,

doi:10.1089/can.2016.0014

Cited by 26 publications

(26 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Literature data indicated, that ECS is upregulated during obesity and associated diseases (81)(82)(83)(84). It is well-confirmed that the level of endogenous cannabinoids in the above mentioned conditions is increased, i.e., in CNS, adipose tissue, pancreas, skeletal muscle, kidney, liver, and blood of obese rodents and humans (76,(84)(85)(86)(87). The cause of such ECS overactivation may be due to enhanced synthesis of ECs or their reduced degradation as well as overexpression of the cannabinoid receptors (88,89).…”

Section: Overactivation Of the Ecs In Obesitymentioning

confidence: 74%

“…Obesity and coexisting disorders such as insulin resistance, hypertension, and hypertriglyceridemia lead to the development of metabolic syndrome and type 2 diabetes (75). Whenever, the excessive fatty acids (FAs) consumption takes place, simultaneously we can observe an increased differentiation of pre-adipocytes to mature adipocytes with subsequent stimulation of their growth as well (76,77). Over time, at a later stage of obesity development, adipocytes are overloaded, which results in the accumulation of lipids in other tissues such as liver, skeletal, and cardiac muscles (60,78).…”

Section: Overactivation Of the Ecs In Obesitymentioning

confidence: 99%

See 1 more Smart Citation

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

2020

View full text Add to dashboard Cite

Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of triacylglycerols (TAGs) in a diet also evokes adipocyte hyperplasia and subsequent accumulation of lipids in peripheral organs (liver, cardiac muscle). Therefore, new therapeutic methods are constantly sought for the prevention, treatment and alleviation of symptoms of the above mentioned diseases. Currently, much attention is paid to Cannabis derivatives-phytocannabinoids, which interact with the endocannabinoid system (ECS) constituents. 9-tetrahydrocannabinol (9-THC) and cannabidiol (CBD) are the most abundant compounds of Cannabis plants and their therapeutic application has been suggested. CBD is considered as a potential therapeutic agent due to its anti-inflammatory, anti-oxidant, anti-tumor, neuroprotective, and potential anti-obesity properties. Therefore, in this review, we especially highlight pharmacological properties of CBD as well as its impact on obesity in different tissues.

show abstract

Section: Overactivation Of the Ecs In Obesitymentioning

confidence: 74%

Section: Overactivation Of the Ecs In Obesitymentioning

confidence: 99%

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

2020

View full text Add to dashboard Cite

show abstract

“…Second, it has been shown that cannabinoids can cause increased glucose intake and lipogenesis. 229 Therefore, if authorizing the use of medicinal cannabis for obese diabetic patients who are receiving insulin injections, the effects of MM on blood glucose levels and the patients’ response to their current treatment regimen should be examined with these underlying impacts in mind, particularly when considering a change in treatment or dose.…”

Section: Methodsmentioning

confidence: 99%

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

Mouhamed¹,

Vishnyakov²,

Qorri³

et al. 2018

DHPS

View full text Add to dashboard Cite

With the proposed Canadian July 2018 legalization of marijuana through the Cannabis Act, a thorough critical analysis of the current trials on the efficacy of medicinal marijuana (MM) as a treatment option is necessary. This review is particularly important for primary care physicians whose patients may be interested in using MM as an alternative therapy. In response to increased interest in MM, Health Canada released a document in 2013 for general practitioners (GPs) as an educational tool on the efficacy of MM in treating some chronic and acute conditions. Although additional studies have filled in some of the gaps since the release of the Health Canada document, conflicting and inconclusive results continue to pose a challenge for physicians. This review aims to supplement the Health Canada document by providing physicians with a critical yet concise update on the recent advancements made regarding the efficacy of MM as a potential therapeutic option. An update to the literature of 2013 is important given the upcoming changes in legislation on the use of marijuana. Also, we briefly highlight the current recommendations provided by Canadian medical colleges on the parameters that need to be considered prior to authorizing MM use, routes of administration as well as a general overview of the endocannabinoid system as it pertains to cannabis. Lastly, we outline the appropriate medical conditions for which the authorization of MM may present as a practical alternative option in improving patient outcomes as well as individual considerations of which GPs should be mindful. The purpose of this paper is to offer physicians an educational tool that provides a necessary, evidence-based analysis of the therapeutic potential of MM and to ensure physicians are making decisions on the therapeutic use of MM in good faith.

show abstract

“…A gyulladásos mediátorok és az adipokinek szekréciójának kedvezőtlen befolyásolása mellett, az ECR egy sor más biológiai funkciót is úgy befolyásol a zsírszövetben, hogy ezek az energiamérleget a takarékoskodás irányába tolják el. Kiemelendőek ezek közül az adipo-és lipogenézis stimulálása, valamint a BAZs-i hatás [10,67,68]. Az in vitro adatok arról tanúskodnak, hogy a CB1 receptor aktiválása a PPARγ expressziót serkenti és a lipid-vakuolák méretét növeli, míg a CB1 gátlása épp ellenkező hatást vált ki [68].…”

Section: Az Endokannabinoid Rendszer éS a Zsírszövet Kapcsolataunclassified

“…Kiemelendőek ezek közül az adipo-és lipogenézis stimulálása, valamint a BAZs-i hatás [10,67,68]. Az in vitro adatok arról tanúskodnak, hogy a CB1 receptor aktiválása a PPARγ expressziót serkenti és a lipid-vakuolák méretét növeli, míg a CB1 gátlása épp ellenkező hatást vált ki [68]. Továbbá, a CB1 aktivációja sejtproliferációt indít be a 3T3-L1 sejtvonalon, és az adipogenézis serkentése során a CB1 receptor expressziója folyamatosan növekszik [69,70].…”

Section: Az Endokannabinoid Rendszer éS a Zsírszövet Kapcsolataunclassified

The endocannabinoid system: from the receptors to therapy

Bába

Kolcsár

Hack

et al. 2019

Bulletin of Medical Sciences

View full text Add to dashboard Cite

The endocannabinoid system (ECS) received a lot of attention ever since its discovery. Advancements of the last three decades have shown that there are numerous mechanisms by which the ECS regulates the energy metabolism. These can either be central (regulating appetite and calorie expenditure) or peripheral (adipocyte-specific and other) mechanisms. The current review highlights some of the most important observations leading to the discovery of the ECS first, followed by a part detailing the synthesis and transport of these mediators, the receptor types and second messenger systems involved. The next part is dedicated to the mechanisms by which this system regulates the energy metabolism. Lastly, the drugs that reached the clinical phase and the main targets and strategies for future drug development will be reviewed.

show abstract

The Fat Side of the Endocannabinoid System: Role of Endocannabinoids in the Adipocyte

Cited by 26 publications

References 85 publications

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

Therapeutic potential of medicinal marijuana: an educational primer for health care professionals

The endocannabinoid system: from the receptors to therapy

Contact Info

Product

Resources

About